Phase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNEPC
Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/0 Comments/in Retrospective studies/by MaxPhase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 3 Trial: Ifinatamab Deruxtecan (MK-2400) for metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: HSK46575 a Novel CYP11A1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Trial: Targeting Resistance With SX-682 And Apalutamide or Enzalutamide
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial for DR-0202 Bispecific Antibody for Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxBRL-302 Phase 1: A New CAR-T Cells Therapy for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data talazoparib theranostics
Latest Posts
- Breakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond July 17, 2025
- How Exercise Boosts Cancer Immunotherapy: The Role of Gut Microbes and Formate July 14, 2025
- Triplet therapy shows strongest survival benefit in mHSPC with visceral disease July 14, 2025
- Newsletter 28/2025 July 13, 2025